Impact of cytochrome P450 3A5 expression on clinical outcomes in renal transplant recipients receiving tacrolimus-based immunosuppression

Table 5 Complications and outcomes observed in expressor vs non-expressors

Variable	Expressors (n = 35)		Non-expressors (n = 60)		P value
	n	%	n	%
New onset diabetes after transplantation
Yes	1	2.9	3	5.0	0.6178
No	34	97.1	57	95.0
Hypomagnesemia
Yes	22	62.9	31	51.7	0.2920
No	13	37.1	29	48.3
Tuberculosis after transplant
Yes	3	8.6	8	13.3	0.8710
No	32	91.4	52	86.7
Tacrolimus discontinued permanently
Yes	8	22.9	10	16.7	0.4600
No	27	77.1	50	83.3
Biopsy-proven acute rejection
Yes	8	22.9	8	13.3	0.2340
No	27	77.1	52	86.7